Get the latest tech news
The Race for the Next Ozempic
Move aside Ozempic. Following their success, drug manufacturers are racing to develop obesity treatments that shed more weight, are easier to take, and produce fewer side effects.
“It’s an extraordinarily exciting and busy time in the field of obesity,” says Darren McGuire, a cardiologist and professor of internal medicine at University of Texas Southwestern Medical Center. Semaglutide and tirzepatide work by activating GLP-1 receptors in the pancreas to stimulate the production of insulin, which helps to control blood sugar levels in people with type 2 diabetes. “We have not seen results like this before in a trial of less than one-year duration with an anti-obesity medication,” said Ania Jastreboff, an endocrinologist and weight specialist at the Yale School of Medicine during a press conference last year at the American Diabetes Association annual meeting.
Or read this on Wired
